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Abstract
Introduction The cytotoxic effects of radiation therapy are
mediated primarily through increased formation of hydroxyl
radicals and reactive oxygen species, which can damage cells,
proteins and DNA; the glutathione S-transferases (GSTs)
function to protect against oxidative stress. We hypothesized
that polymorphisms encoding reduced or absent activity in the
GSTs might result in greater risk for radiation-associated
toxicity.
Methods Women receiving therapy in radiation units in
Germany following lumpectomy for breast cancer (1998–2001)
provided a blood sample and completed an epidemiological
questionnaire (n  = 446). Genotypes were determined using
Sequonom MALDI-TOF (GSTA1,  GSTP1) and Masscode
(GSTM1,  GSTT1). Biologically effective radiotherapy dose
(BED) was calculated, accounting for differences in
fractionation and overall treatment time. Side effects considered
were grade 2c and above, as classified using the modified
Common Toxicity Criteria. Predictors of toxicity were modelled
using Cox regression models in relation to BED, with adjustment
for treating clinic, photon field, beam energy and boost method,
and potential confounding variables.
Results Low activity GSTP1 genotypes were associated with a
greater than twofold increase in risk for acute skin toxicities
(adjusted hazard ratio 2.28, 95% confidence interval 1.04–
4.99). No associations were noted for the other GST genotypes.
Conclusion These data indicate that GSTP1 plays an important
role in protecting normal cells from damage associated with
radiation therapy. Studies examining the effects of GSTP1
polymorphisms on toxicity, recurrence and survival will further
inform individualized therapeutics based on genotypes.
Introduction
Breast conserving surgery followed by radiation therapy has
been shown to be as effective as mastectomy in preventing
breast cancer mortality [1], and use of this approach in women
with localized disease is common. Although breast irradiation
is fairly well tolerated, treatment is often associated with short
term side effects, including skin erythema and irritation, as well
as medium-term and long-term side effects of breast edema,
pain, fibrosis, and telangiectasia [2]. Side effects of radiation
therapy have been shown to have an impact on quality of life,
with women undergoing therapy exhibiting a decrease in over-
all quality of life during treatment, measured by a modified
Breast Cancer Chemotherapy Questionnaire, compared with
those who did not have breast irradiation following surgery [3].
Breast irritation and pain were greatest among women who
had longer term therapy.
BED = biologically effective dose; BMI = body mass index; GST = glutathione S-transferase; PCR = polymerase chain reaction; ROS = reactive 
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In breast cancer, effort has been made to identify factors other
than radiation dose that may predispose to damage to normal
tissue in the targeting of residual cancer cells with radiation
therapy following lumpectomy. In previous investigations,
systolic blood pressure [4], breast size [5], and age [6] were
associated with acute skin reactions in breast cancer patients.
In a prospective cohort of women with breast cancer receiving
radiation therapy following lumpectomy, with carefully calcu-
lated dose and monitored acute skin toxicity, we noted that
higher body mass index (BMI), but not DNA repair capacity,
was associated with acute side effects [7].
These factors explain only a portion of the variability in acute
side effects of radiation therapy, and efforts have been made
to identify genetic factors that could make normal cells more
sensitive to contralateral damage with treatment. Radiation
therapy exerts its cytotoxic effects through direct action
(imparting energy to electrons that damage DNA directly) and
indirect action [8] by producing reactive oxygen species
(ROS), including superoxide radicals, hydrogen peroxide, and
hydroxyl radicals [9,10]. Thus, it is plausible that genetic varia-
bility in protection from oxidative stress could influence sus-
ceptibility to acute side effects in women receiving radiation
therapy. Glutathione-associated metabolism is a major mech-
anism for cellular protection against ROS and their toxic prod-
ucts, and glutathione S-transferases (GSTs) α, µ, π, and θ are
active in detoxifying organic epoxides, hydroperoxides, and
unsaturated aldehydes, including reactive bases and lipid per-
oxides produced by reactive oxidant damage to DNA and lip-
ids, respectively [11,12]. GSTM1 and GSTT1 both contain
gene deletions, resulting in no enzymatic activity for that iso-
zyme. The GSTA1*A and GSTA1*B genetic polymorphism
(RS3957357), containing three linked base substitutions in
the promoter at positions -567, -69, and -52, results in differ-
ential expression [13], with lower transcriptional activation of
the GSTA1*B (variant) than of the GSTA1*A (common) allele
in vitro [14]. The GSTP1 isoleucine105valine substitution is
also associated with reduced activity [15].
Reduced detoxification of ROS and their products resulting
from polymorphisms in genes encoding GSTs could be
responsible for greater acute toxicities among women receiv-
ing radiation therapy. In a prospective study of genetic and
nongenetic factors that could influence the effects of radiation
therapy on normal tissue, we evaluated the role of polymor-
phisms in GST genes GSTM1, GSTT1, GSTA1 and GSTP1
in predicting acute side effects.
Materials and methods
For this study of genetic and nongenetic predictors of skin tox-
icity associated with radiation therapy, an unselected cohort of
women with breast cancer was recruited from several radio-
therapy units in Germany from 1998 to 2001. As previously
described [7,16], women were eligible if they were receiving
primary radiation therapy following breast conserving surgery
and had not previously received chemotherapy. Participating
radiotherapy units included those of the Women's Clinic in
Heidelberg, the University Hospital of Mannheim, the St. Vin-
centius Clinic in Karlsruhe, and the City Hospital of Karlsruhe.
Women were all Caucasian and there were no age restric-
tions; informed consent was obtained from all patients. Of the
506 patients recruited, eight were excluded because of unsat-
isfactory data collection, and 20 patients withdrew their con-
sent during the period of data collection, for a total of 478
patients for whom data were available for the present analysis.
The study was approved by the Ethical Committee of the Uni-
versity of Heidelberg, the Institutional Review Board for
Roswell Park Cancer Institute, and the US Army Medical
Research and Materiel Command Human Subjects Research
Review Board. Participants were asked to complete a ques-
tionnaire with epidemiologic information on demographic and
lifestyle factors, medical history, and family history of breast
cancer. Permission was also requested to incorporate clinical
data (tumor characteristics and therapy regimen) into the
research database, and for collection of a blood specimen
before the initiation of radiation therapy.
As previously described [16], all patients received standard
breast irradiation treatments, including computed tomography
based planning, simulation, verification, and quality assurance,
with conformal tangential irradiation with lateral and medial
wedge fields. All regimens included irradiation of the entire
breast. At three units, women received either 50 Gy given in
five 2.0 Gy fractions per week or 50.4 Gy given in five 1.8 Gy
fractions per week, followed by boost radiation from 6 to 25
Gy. At the fourth radiation department, 56 Gy of whole breast
irradiation were applied in five 2.0 Gy fractions per week with-
out a boost. To account for differences in fractionation and
overall treatment time, the biologically effective radiation ther-
apy dose (BED) was calculated using the following formula:
,          
where n is the number of fractions, d is the fraction size, α/β is
the ratio for acute skin reactions (10 Gy), γ/α is the time factor
(0.7 Gy/day), T is the overall treatment time, and T0 is the start-
ing time for compensatory proliferation of 21 days [17]. The
average BED for radiotherapy by censoring was 54.0 ± 4.8
Gy, with a range from 35.5 to 64.5 Gy.
Side effects were carefully monitored and recorded by treating
physicians, and toxicities were documented four times during
the study. These included before the beginning of therapy, and
at cumulative doses of 36–42 Gy, 44–50 Gy, and 60–66 Gy
(end of radiation therapy). Acute side effects were classified
using a modified system based on the Common Toxicity Crite-
ria of the Cancer Therapy Evaluation Program (National Insti-
tutes of Health, 1998 [18]. For this analysis, we included only
acute side effects of grade 2c and above, which is categorized
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by at least one moist desquamation or interruption of radio-
therapy due to toxicity [19]. Of the patients who provided a
blood specimen (n = 446), 77 women presented with toxicity
of grade greater than 2c.
Genomic DNA from pretreatment blood samples was
extracted from lymphocytes using the QIAamp DNA Blood
Midi Kit (Qiagen, Hilden, Germany), in accordance with the
manufacturer's instructions. All DNA preparations were stored
at 4°C until use. Genotyping for polymorphisms in GSTA1 and
GSTP1 was performed by BioServe Biotechnologies (Laurel,
MD, USA) using Sequenom's (San Diego, CA, USA) high-
throughput matrix-assisted laser desorption/ionization time-of-
flight (MALDI-TOF) mass spectrometry.





3'. A multiplex PCR technique that detects homozygous dele-
tions of GSTM1 and GSTT1 was used, including primers for
the β-globin gene as an internal control, with an annealing tem-
perature of 62°C [20]. For GSTM1, primers 5'-GAACTCCCT-
GAAAAGCTAAAGC-3' and 5'-GTTGGGCTCAAA TAT
ACGGTGG-3' were used; and for GSTT1, primers T1 (5'-
TTCCTTACTGGTCCTCACATCTC) and T2 (5'-TCACCG-
GATCATGGCCAGCA) were used. The absence of amplified
GSTM1 or GSTT1 product (in the presence of the albumin
PCR product) indicated the respective null genotype for each.
Table 1
Patient characteristics and skin toxicity (>2c) among women receiving radiation therapy following breast conserving surgery
Characteristics Patients (n) Toxicities (n)H R a (95% CI)
Age (years)
≤50 62 11 1.0
>50 to 60 168 36 1.29 (0.65–2.57)
>60 to 70 152 23 0.84 (0.41–1.76)
>70 65 8 0.78 (0.31–1.97)
BMI (kg/m2)
≤25 229 23 1.0
26–30 150 36 2.50 (1.45–4.30)
>30 68 19 3.30 (1.76–6.21)
Skin sensitivity
Always sunburn 113 17 1.0
Sometimes sunburn 243 43 1.15 (0.65–2.04)
Never sunburn 80 16 1.49 (0.74–2.99)
Current smoking
No 399 67 1.0
Yes 48 11 1.54 (0.79–3.01)
Alcohol consumption
No 110 12 1.0
Yes 321 61 1.88 (1.00–3.53)
Radiotherapy of lymph nodes
No 397 67 1.0
Yes 50 11 1.32 (0.66–2.63)
Hormone therapy
No 68 9 1.0
Yes 379 69 1.51 (0.75–3.04)
aHazard ratio adjusted for clinic, photon field, beam energy, and boost method; numbers vary because of missing data. BMI, body mass index; CI, 
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All genotyping results were reviewed manually for quality con-
trol. Controls for genotype and two 'no template' controls were
included on each plate. In addition, 170 sets of blinded con-
trols (8%) were distributed throughout the plates for quality
control purposes. Because there were differential failures in
genotyping by gene, numbers vary somewhat in the tables and
columns.
The associations of toxicity with personal or treatment charac-
teristics (age, BMI, skin sensitivity, skin disease, smoking sta-
tus, alcohol use, radiotherapy of lymph nodes and hormone
therapy), as well as genotypes (GSTM1, GSTT1, GSTA1, and
GSTP1), were analyzed using the Cox model. Univariate anal-
ysis for each factor was conducted initially to estimate crude
associations. To be included in the model for multivariate anal-
ysis, the variable had to be potentially significant (P < 0.30
with the likelihood ratio test) by univariate analysis. The relative
hazard (with 95% confidence interval) for toxicity compared
with a reference group was also estimated as an indication of
the strength of the possible association. Because the treat-
ment algorithm was slightly different across four clinics, and
photon-field and boost method are considered the additional
factors affecting toxicity to biologic dose, the Cox regression
analysis was conducted adjusted for photon and boost meth-
ods, as well as stratified by clinic. This strategy was imple-
mented to control for dose and other treatment factors. The
toxicity-free (without toxicity of grade 2c or greater) probability
along with BED was estimated using the Kaplan-Meier
method. All the analyses were performed using SAS 9.1 (SAS
Institute, Cary, NC, USA) software.
Results
As previously reported [7] and shown in Table 1, of all demo-
graphic and epidemiologic factors evaluated, only BMI was
associated with a greater risk for experiencing severe skin tox-
icities following radiation therapy, although there was an asso-
ciation of borderline significance with alcohol consumption
(yes/no). When evaluating the potential effects of genotypes
associated with reduced or absent activity for the GSTs, we
found that GSTP1 GG genotypes, associated with reduced
enzyme activity, were significantly associated with acute side
effects of radiation therapy (Figure 1). When models were
adjusted for clinic, photon field, beam energy, boost method,
BMI, smoking status, alcohol consumption, and hormone ther-
apy (Table 2), there was more than a twofold increase in haz-
ard of toxicity among women with GSTP1  GG genotypes
(adjusted hazard ratio 2.28, 95% confidence interval 1.04–
4.99), in comparison with women with common AA geno-
types. Although there was a slight increase in risk in women
with heterozygous genotypes, suggesting a dose-response
effect, the association was not statistically significant (hazard
ratio 1.38, 95% confidence interval 0.83–2.30), although
there was a significant gene dosage effect (P = 0.04). There
were no associations noted for GSTM1, GSTT1, or GSTA1.
When 'at-risk' alleles were combined (Table 3), and women
with two or more alleles related to reduced or absent activity
were contrasted with those with 0 or 1 low activity alleles, no
cumulative effects were noted.
Discussion
In this analysis of potential relationships between genotypes
related to reduced protection from ROS and severe side
effects of radiation therapy following lumpectomy for breast
cancer, we found that carrying the GSTP1 isoleucine105valine
substitution (GG genotype) was associated with a more than
twofold increase in risk for experiencing acute skin toxicities.
Genotypes associated with reduced or absent activity for
GSTM1,  GSTT1, and GSTA1  were not associated with
increased toxicity.
To our knowledge, there have been no evaluations of the role
of genotypes associated with decreased GST activity and side
effects experienced with radiation therapy. However, there
have been a number of studies designed to address the
effects of GST genotypes on survival and secondary malignan-
cies after treatment for cancer, with several – although not all
– studies finding an important role for GSTP1 polymorphisms
in treatment outcomes. In a study of patients with Hodgkin's
lymphoma [21], the low activity GSTP1 genotype was associ-
ated with better survival. In that population, patients were
treated with a number of chemotherapeutic agents, so the
mechanism is not specific to radiation-generated ROS. Similar
relationships with GSTP1 were noted in a study of patients
with esophageal cancer [22], with no effects on survival
observed for GSTM1 and GSTT1. This patient population did
include those who did not receive adjuvant therapy, and the
survival effects were observed among both treated and
untreated populations. However, in another study that meas-
ured GSTP1 expression in esophageal tissue among patients
Figure 1
Probability of toxicity-free effects Probability of toxicity-free effects. Kaplan-Meier curve for the probability 
of toxicity-free effects (without Common Toxicity Criteria grade 2c tox-
icity or greater) by GSTP1 genotypes.Available online http://breast-cancer-research.com/content/8/4/R40
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receiving chemoradiation, higher expression was associated
with poorer survival [23], strengthening the hypothesis that
reduced levels of GSTP1 are associated with greater cell kill.
In an earlier study of women receiving treatment for breast
cancer, we found that low activity GSTP1 genotypes were
associated with better survival [24], and these results were
replicated in the Shanghai Breast Cancer Study [25]. In our
earlier study [24] the majority of women received chemother-
apy plus radiation therapy, and in the Yang study only chemo-
therapy was administered as adjuvant therapy. To our
knowledge, one study assessed genetic polymorphisms and
susceptibility to radiotherapy-related malignancies, but only
evaluated GSTM1 and GSTT1, finding nonsignificant elevated
risk for second cancers among those with gene deletions [26].
Assessment of relationships between GST polymorphisms
and survival following cancer treatment is based on the
hypothesis that reduced GST activity would result in fewer
ROS and therapeutic agent metabolites reaching tumor cells,
where they could confer protection against damage to DNA,
proteins, and lipids. Our investigation of toxicities associated
with radiation therapy following lumpectomy is based on the
premise that this same inability to block ROS might result in
better tumor cell kill but also in concomitant damage to normal
tissue in the breast, demonstrated by adverse skin toxicities.
There is an absence of data regarding this issue, although ear-
lier work did show that prevention of breast cancer relapse
with radiation therapy was greatest among women with ele-
vated levels of GST π protein in tumor tissue, supporting a role
for GSTP1 in response to radiation therapy [27]. Because
radiation results in generation of ROS and lipid peroxidation,
the finding that nuclear GST π plays a role in the cellular sen-
sitivity to oxidative stress caused by hydrogen peroxide
through scavenging the formation of lipid-peroxide modified
DNA [28] further support our findings.
Our confidence in the finding reported here, namely that low
activity GSTP1 genotypes are associated with greater skin
toxicity following radiation therapy, is bolstered by the design
of the study and careful assessment of toxicity outcomes. This
study was specifically designed and conducted to determine
the role of genetic factors in skin toxicities, with a priori hypoth-
eses established before implementation of the study. Each
radiation dose was recorded, and cumulative radiation dose
was calculated. Women were monitored and scored for skin
toxicities according to cumulative dose time points, and were
categorized according to the Common Toxicity Criteria of the
National Institutes of Health.
In this same cohort, we previously evaluated the role of poly-
morphisms in DNA repair genes (XPD, XRCC1, and APE) in
acute side effects of radiation [16]. No effects were noted
among the total population, but when analyses were limited to
women of normal weight, risk for side effects was greatly
Table 2
Associations between polymorphisms in GST genes and skin toxicity (≥2c) following radiation therapy for breast cancer
Genotypes Patients Toxicities HRa (95% CI)
GSTM1
Present 215 36 1.0
Absent 213 39 1.23 (0.74–2.03)
GSTT1
Present 384 69 1.0
Absent 55 6 0.73 (0.29–1.86)
GSTA1
GG 149 29 1.0
GA 194 35 1.09 (0.65–1.82)
AA 87 12 0.85 (0.43–1.71)
P (trend) = 0.44
GSTP1
AA 176 27 1.0
AG 213 39 1.38 (0.83–2.30)
GG 38 10 2.28 (1.04–4.99)
P (trend) = 0.04
aHazard ratio adjusted for clinic, photon field, beam energy, boost method, BMI, smoking status, alcohol consumption, and hormone therapy; 
numbers vary because of missing data. CI, confidence interval; GST, glutathione S-transferase; HR, hazard ratio.Breast Cancer Research    Vol 8 No 4    Ambrosone et al.
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reduced among carriers of APE1 148Glu and XRCC1 399Gln
alleles, with no reduced risk observed among overweight and
obese women. We did not note an effect of BMI in our analy-
ses (data not shown), but we did observe the associations
between greater toxicity and low activity GSTP1 genotypes
among the entire study group.
Conclusion
In summary, in this carefully designed and conducted study of
genetic predictors of acute side effects from radiation therapy
following lumpectomy for breast cancer, we found that women
with GSTP1 genotypes encoding lower activity were more
likely to experience toxicity of grade 2c and above. These find-
ings are consistent with several studies that found better sur-
vival among cancer patients with low activity GSTP1 alleles,
implying that genotypes associated with lower GSTP1 activity
allow reactive intermediates to interact with and damage both
tumor and normal cells. Of course, therapeutic decisions
regarding optimal dose must strike a balance between treat-
ment efficacy in preventing cancer recurrence and reducing
severe side effects. Studies that incorporate such measures
(toxicities, recurrence, and survival) will help to clarify this
issue and provide clinically relevant data on the utility of using
genotypes for individualized therapeutics.
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